New cancer immunotherapy targeting multiple receptors has entered the clinic

, the Swiss-based Immun Os Therapeutics company received 15 million Swiss francs (about $15.2 million) in round a round of financing to advance its new cancer immunotherapy into clinical trials. The round of financing is led by Pfizer Ventures and BioMed Partners and is funded by companies such as Redalpine and Schroder Adveq.The round of financing is primarily intended to support the company's potential new immunotherapy for solid and blood tumors, iosH2, into clinical trials, and will also be used to advance the company's preclinical development program for other drug candidates and expand its new immunotherapy platform. Unlike common cancer antibody therapies, the new generation of cancer immunotherapy can target multiple subjects with a molecule to activate anti-tumor synergies between immune cells, according to the company's official website. In addition, the therapy can reshape the tumor micro-environment to enhance the efficacy of existing immunotherapy. Three drug candidates are currently in preclinical development under its research and development pipeline: iosH2, iosH5 and iosH1.While raising funds, the company added four executives from leading pharmaceutical companies and venture capital to the board, including Dr. Markus Hosang of BioMed Partners, Dr. Michael Baran of Pfizer, Dr. Reinhard Ambros, former head of Novardo Ventures, and Dr. Daniel Vasella, former Chief Executive Officer of Novardo.“ Our understanding of the role of the innant immune system in cancer development provides us and our partners with a unique opportunity to work together," said Sean R. Smith, CEO of ImmunOs Therapeutics. " advances in understanding the role of the innariable immune system offer an opportunity to expand the potential of cancer immunotherapy," said Dr. Michael Baran of Pfizer. "(Creative Exchange) is